What is the rating for MRM stock?

Medirom Healthcare Technologies Inc. (MRM) has a "Reduce" rating based on our 6-factor quantitative model. It has a composite score of 49.7 and ranks #2053 out of 7,333 stocks in our coverage universe with a 2-star rating.

Is MRM a good stock to buy?

Based on our quantitative analysis, MRM receives a "Reduce" rating with 2 out of 5 stars. Key factors include: Quality score of 49.4, Value score of 52.1, and Momentum score of 59.8. The timing score is 42, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is MRM in?

Medirom Healthcare Technologies Inc. (MRM) operates in the Services sector, specifically in the Personal Services industry. It has a market capitalization of $0.00 billion.

What is MRM's P/E ratio?

MRM has a P/E (Price-to-Earnings) ratio of 7.40x. This helps investors assess whether the stock is trading at a premium or discount relative to its earnings.

Does MRM pay a dividend?

MRM does not currently pay a dividend.

What is MRM's market cap?

Medirom Healthcare Technologies Inc. (MRM) has a market capitalization of $0.00 billion, making it a micro-cap stock.

What are the risks of investing in MRM?

Key risk factors for MRM include: higher volatility, elevated debt levels, and general market risk. As with all investments, there is risk of loss.

How does MRM compare to peers?

Within the Services sector, MRM ranks #2053 overall with a quality score of 49.4/100 and value score of 52.1/100.

What is MRM's revenue growth?

Revenue growth data is not currently available for MRM.

What is MRM's composite score?

Medirom Healthcare Technologies Inc. (MRM) has a composite score of 49.7/100, which places it at rank #2053 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does MRM compare to the S&P 500?

MRM ranks in the top 72% of all stocks in our coverage universe with a composite score of 49.7.

What are the bull and bear cases for MRM?

Bull case: MRM scores highest in momentum at 59.8/100, indicating strong performance in this area. Bear case: The weakest factor is investment efficiency at 42/100, which may present a risk. Our overall assessment is Reduce with 2 out of 5 stars.

Is MRM overvalued or undervalued?

MRM appears fairly valued with a value factor score of 52.1/100.

What is MRM's momentum score?

MRM has a momentum score of 59.8/100, placing it in the moderate category.

When is MRM's next earnings date?

For the latest earnings date and analysis for MRM, visit our earnings calendar or check the MRM stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is MRM a good stock to buy right now?

Based on our 6-factor quantitative model, Medirom Healthcare Technologies Inc. (MRM) receives a "Reduce" rating with a composite score of 49.7/100. It is ranked #2053 out of 7,333 stocks. Key factor scores: Quality 49/100, Value 52/100, Momentum 60/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for MRM?

Medirom Healthcare Technologies Inc. (MRM) has a "Reduce" rating and 2-star score. The composite score of 49.7 ranks it #2053 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is MRM in?

Medirom Healthcare Technologies Inc. operates in the Services sector (Personal Services industry) with a market cap of $0. It is classified as a micro-cap stock.

Does MRM pay a dividend?

MRM does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is MRM's P/E ratio?

MRM has a trailing P/E ratio of 7.40x. The Services sector average is 23.7x. This below-average P/E may indicate the stock is undervalued.

How profitable is MRM?

MRM's quality factor score is 49/100. Gross margin: 27.1%. ROE: 59.2% vs sector average 5.7%. Margins are moderate to low, reflecting competitive market dynamics.

How is MRM valued compared to peers?

MRM's value factor score is 52/100 (higher = cheaper). Key multiples: P/E 7.4x, EV/EBITDA 2.1x. Valuation is roughly in line with peers.

What is MRM's debt level?

MRM's debt-to-equity ratio is 201%. Sector average: 0%. Elevated leverage increases credit risk.

MRM has a beta of -0.03, meaning it is less volatile than the market. Stability score: 44/100.

Does MRM have high short interest?

MRM's short interest factor score is 55/100 (higher = less short selling). Moderate short interest.

MRM Stock Analysis — Medirom Healthcare Technologies Inc. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

MRM Stock Analysis — Medirom Healthcare Technologies Inc. Price Target & Forecast 2026 | Blank Capital Research

Sector

Services

Industry

Personal Services

Market Cap

Leadership

Koji Eguchi

Business Summary

MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment. Digital Preventative Healthcare segment offers government-sponsored Specific Health Guidance program.

Operations

Headcount

480

Location

HQ Base

Pending Verification

Investor Relations

Fundamental Spot Check

Context: 2024

Valuation

Market Cap

P/E Ratio

7.4xOutperforming

P/B Ratio

1.83xOutperforming

P/S Ratio

0.05xOutperforming

EV/EBITDA

2.1xOutperforming

Dividend Yield

Efficiency & Risk

Gross Margin

27.1%Lagging

Operating Margin

-0.2%Lagging

ROE

59.2%Outperforming

Rev Growth (YoY)

Debt/Equity

201.00xLagging

Beta

-0.03

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

60th pctl

Intelligence Feed

simplywall.stJan 30 Neutral

MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) Might Not Be As Mispriced As It Looks

When you see that almost half of the companies in the Consumer Services industry in the United States have...

yahooJan 8 Positive

World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku’s “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

TOKYO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), announces that the cumulative number of Proof of Human authentications using the World ID authentication device ‘Orb’ at stores centered on the relaxation salon “Re.Ra.Ku,” operated by its subsidiary MEDIROM Wellness Co., surpassed 20,000 as of December 28, 2025. The Company participates in World (a Proof of Human authentication

benzinga.comJan 8 Positive

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

BenzingaSep 26 Neutral

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket

Top KingWin shares surged 87.4% in pre-market trading after announcing a sales contract for 10,000 AI Robots. Several other stocks showed significant movement, with some gaining and others declining based on company-specific news and financial results.

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • MRM

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021	2020	2019
Revenue		$53M8.8%	$48M8.2%	$53M12.3%	$47M45.1%	$32M10.1%	$36M
Cost of Revenue		$38M3.1%	$37M2.6%	$38M10.5%	$35M23.0%	$28M3.6%	$27M
Gross Profit		$14M28.2%	$11M22.9%	$14M17.4%	$12M195.8%	$4M52.5%	$9M
R&D Expense	-	—	—	—	—	—	—
Operating Expenses		$14M3.4%	$14M1.6%	$14M16.4%	$16M43.9%	$11M34.9%	$8M
Operating Income		-$115K95.9%	-$3M477.7%	$736K118.0%	-$4M43.5%	-$7M	$316K
Interest Expense		$316K20.8%	$262K251.9%	$74K28.3%	$104K19.0%	$128K2.4%	$125K
Tax Provision		-$575K14.2%	-$670K386.7%	$234K95.3%	$5M690.3%	-$848K676.8%	$147K
EBITDA		$2M12.3%	$2M21.4%	$3M215.9%	-$2M55.0%	-$5M737.6%	$839K
Net Income		$878K7.6%	$816K27.8%	$1M113.1%	-$9M64.7%	-$5M	$160K
EPS (Diluted)		$0.1910.3%	$0.1799.5%	$30.54115.0%	$-203.1351.6%	$-133.97	$4.63

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for MRM.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Gross Margin

Core pricing power

-58% SCTR

27.1%

Sector Avg: 64.6%

Operating Margin

Operating efficiency

-105% SCTR

-0.2%

Sector Avg: 4.5%

Return on Equity

Equity efficiency

+932% SCTR

59.2%

Sector Avg: 5.7%

Debt/Equity

Financial leverage

-57329% SCTR

201.0%

Sector Avg: 0.3%

Financial History

Forensic Accounting Audit

Watchlist

Asset Efficiency

Improving capital utilization rates confirmed

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Koji Eguchi

Insider alignment Audit

No recent insider transactions available for MRM

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Services Universe

Factor Alpha Dispersion: Value vs. Quality

Quadrant I: High Quality / Undervalued

Quadrant III: Low Quality / Expensive

X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = MRM ANALYSIS TARGET

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$YALA Yalla Group Ltd		75	89	99	80	-	-	-	-	-	-	-	-	-	-	$0	VS
$GRVY GRAVITY Co., Ltd.		75	82	96	71	-	-	-	-	-	-	-	-	-	-	$0	VS
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC		73	81	88	94	25.0x	14.1x	17.1%	10.3%	35.5%	14.6%	10.1%	105.2%	0.0%	41.0x	$244M	VS
$AER AerCap Holdings N.V.		72	60	87	84	-	-	-	-	-	-	-	-	-	-	$0	VS
$HCSG HEALTHCARE SERVICES GROUP INC		72	74	88	88	7.1x	6.1x	28.9%	20.8%	20.8%	9.9%	9.3%	8.5%	0.0%	1.0x	$1.2B	VS
$LQDT LIQUIDITY SERVICES INC		72	90	88	68	24.9x	14.3x	14.1%	8.3%	45.7%	8.5%	6.2%	28.1%	0.0%	0.0x	$736M	VS
$TRTNpA Triton International Ltd		71	70	89	70	-	1.7x	0.0%	-	97.4%	58.0%	37.4%	-	8.8%	264.0x	$2.5B	VS
$EDU New Oriental Education & Technology Group Inc.		71	83	52	77	-	-	-	-	-	-	-	-	-	-	$0	VS
$NTES NetEase, Inc.		71	88	93	68	-	-	-	-	-	-	-	-	-	-	$0	VS
$UTI UNIVERSAL TECHNICAL INSTITUTE INC		70	86	86	72	43.2x	16.0x	15.3%	5.8%	100.0%	6.9%	5.2%	15.1%	0.0%	24.0x	$1.8B	VS
$MRM Medirom Healthcare Technologies Inc.		50	49	52	60	7.4x	2.1x	59.2%	6.8%	27.1%	-0.2%	1.7%	-	-	201.0x	$0
SECTOR BENCH	-	-	-	-	-	23.7x	11.7x	5.7%	2.4%	64.6%	4.5%	2.8%	8.6%	0.0%	0.3x	-	REF

Access Full Services Intelligence Archive →

Lateral Comparison Mesh

$MRM / $YALA AUDIT $MRM / $GRVY AUDIT $MRM / $ISSC AUDIT $MRM / $AER AUDIT $MRM / $HCSG AUDIT

Market Intelligence FAQ

Medirom Healthcare Technologies Inc. (MRM) receives a "Reduce" rating with a composite score of 49.7/100. It ranks #2053 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Medirom Healthcare Technologies Inc. (MRM)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $1.31

Price$1.31

Composite Score49.7/100

RatingREDUCE (2★)

Rank#2053 OF 7,333

Market Cap$0

Comments

Institutional Audit

Feb 25, 2026

Medirom Healthcare Technologies Inc.

49.7

Sector Decomposition auditServices [N=802]

Factor	Global	Sector	Tilt
PROFITABILITY	49	56	-7DRAG
MOMENTUM	60	63	-3NEUTRAL
VALUATION	52	56	-4NEUTRAL
INVESTMENT	42	72	-30DRAG
STABILITY	44	43	+1NEUTRAL
SHORT INT	55	67	-12DRAG

Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.

Executive Summary

Medirom Healthcare Technologies Inc. receives a Reduce rating from our analysis, with a composite score of 49.7/100 and 2 out of 5 stars, ranking #2053 out of 7,333 stocks. MRM's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.

Business Quality

With a quality score of 49/100, MRM shows adequate but unremarkable business quality. The company reports a return on equity of 59.2% (sector avg: 5.7%), gross margins of 27.1% (sector avg: 64.6%), net margins of 1.7% (sector avg: 2.8%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.

Intrinsic Valuation

MRM's value score of 52/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 7.40x, an EV/EBITDA of 2.10x, a P/B ratio of 1.83x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.

Capital Reinvestment

With an investment score of 42/100, MRM exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of 6.8% (sector: 2.4%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.

Market Momentum

MRM demonstrates moderate momentum with a score of 60/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of -0.03 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.

Balance Sheet Health

MRM's stability score of 44/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -0.03 and a debt-to-equity ratio of 201.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.

Institutional Risk Profile

The short interest score of 55/100 for MRM suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 201.00x), micro-cap liquidity risk. With a $0 market cap (micro-cap), Medirom Healthcare Technologies Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.

Sector Benchmark Analysis

Medirom Healthcare Technologies Inc. is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #2053 of 7,333 overall (72nd percentile). Key comparisons include ROE of 59.2% exceeding the 5.7% sector median and operating margins of -0.2% below the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.

Comparative Research Mesh

MRM VS S&P 500 (SPY)TOP SERVICES PEERS

Strategic Alternatives

While MRM currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Services Alpha →

MRM

Medirom Healthcare Technologies Inc.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) Might Not Be As Mispriced As It Looks

World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku’s “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Factor Alpha Dispersion: Value vs. Quality

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

SEC Risk Factors

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

BEAR THESIS

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) Might Not Be As Mispriced As It Looks

World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku’s “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket